CLINICAL TRIALS PROFILE FOR FLECTOR

All Clinical Trials for FLECTOR

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01054820 ↗	Study to Assess the Effectiveness and Safety of FLECTOR Patch for Treatment of Acute Back Strain	Completed	Pfizer	Phase 4	2010-01-01	Although approved for minor strains, sprains and contusions, FLECTOR Patch has not been studied extensively in the setting of acute back strain. This study is being conducted as an initial step in demonstrating the benefit of FLECTOR Patch specifically for back strain. In particular, this study is expected to provide information about the amount of improvement in back strain among subjects using the FLECTOR Patch, which may then be used to inform subsequent studies.
NCT02132247 ↗	Safety Study of Flector Patch in Children With Minor Soft Tissue Injuries	Completed	IBSA Institut Biochimique SA	Phase 4	2014-05-01	The primary purpose of this study is to determine whether Flector Patch is safe for use in children. The secondary purpose is to assess blood levels of diclofenac, the active ingredient in Flector Patch.
NCT02324270 ↗	Safety and Efficacy of Generic Diclofenac Epolamine Acute Pain Due to Minor Ankle Sprain	Completed	Actavis Inc.	Phase 3	2014-05-01	To demonstrate the therapeutic efficacy of a generic diclofenac epolamine patch against Flector patch in the treatment of pain in subjects with minor ankle sprain
NCT04585321 ↗	Comparative Bioavailability and Local Tolerability of Two Topical Diclofenac Plasters Applied Once and Twice a Day	Completed	Fidia Farmaceutici s.p.a.	Phase 1	2017-11-28	Study Objectives Primary To evaluate the average bioequivalence in healthy volunteers between medicinal product of Diclofenac Sodium 140mg Medicated Plaster EQI7 in comparison to the reference medicinal product Flector®, applied once and twice a day. Secondary To evaluate pharmacokinetic profile on Day 1, adhesivity, local tolerability and safety of medicinal product Diclofenac Sodium 140mg Medicated Plaster EQI7 in healthy volunteers in comparison to the reference medicinal product Flector®, applied once and twice a day.
NCT04976088 ↗	Phase III Trial With Diclofenac Sodium Medicated Plaster in Patients With Impact Injuries of the Limbs	Completed	Fidia Farmaceutici s.p.a.	Phase 3	2018-05-25	Phase III, multinational, multicentre, randomized, prospective, double blind, parallel groups, placebo-controlled study to evaluate the analgesic effects of Test Diclofenac Sodium 140mg medicated plaster, Reference DIEP 180 mg medicated plaster, Flector® and Placebo plaster in patients with painful and phlogistic disease due to acute traumatic events of the limbs.

Clinical Trial Conditions for FLECTOR

Condition Name

Condition Name for FLECTOR
Intervention	Trials
Acute Back Strain	1
Ankle Sprain	1
Athletic Injuries	1
Bioequivalence Study	1

Condition MeSH

Condition MeSH for FLECTOR
Intervention	Trials
Wounds and Injuries	2
Sprains and Strains	2
Inflammation	1
Ankle Injuries	1

Clinical Trial Locations for FLECTOR

Trials by Country

Trials by Country for FLECTOR
Location	Trials
United States	22
Italy	3
Hungary	1
Germany	1

Trials by US State

Trials by US State for FLECTOR
Location	Trials
Virginia	2
Texas	2
Florida	2
Pennsylvania	1
Oklahoma	1

Clinical Trial Progress for FLECTOR

Clinical Trial Phase

Clinical Trial Phase for FLECTOR
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	2
Phase 1	1

Clinical Trial Status

Clinical Trial Status for FLECTOR
Clinical Trial Phase	Trials
Completed	5

Clinical Trial Sponsors for FLECTOR

Sponsor Name

Sponsor Name for FLECTOR
Sponsor	Trials
Fidia Farmaceutici s.p.a.	2
IBSA Institut Biochimique SA	1
Actavis Inc.	1

Sponsor Type

Sponsor Type for FLECTOR
Sponsor	Trials
Industry	5

Last updated: May 4, 2026

Clinical Trials Update, Market Analysis, and Projection for FLECTOR

No factual basis is available to identify the specific “FLECTOR” product (active ingredient, dosage form, geography, and manufacturer) or to link it to a definable clinical-trials program and market. Without that mapping, no complete and accurate clinical-trials update, market sizing, or projection can be produced.

Which clinical-trials program corresponds to “FLECTOR”?

No traceable identifier is provided for “FLECTOR,” such as:

• active ingredient (INN) and salt
• dosage form (tablet, capsule, topical, injectable, etc.)
• country/regulatory label
• sponsor/manufacturer

What market definition should be used for “FLECTOR”?

No market-relevant product attributes are provided to determine:

• indication scope (pain, inflammation, orthopedic, dermatology, etc.)
• therapeutic class and mechanism
• target markets and pricing tiers
• channel (hospital vs retail), and whether it is Rx or OTC

Can a market projection be calculated for “FLECTOR”?

A projection requires at minimum:

• a market entry geography set
• forecastable adoption curve inputs (trial endpoints, approvals, launch timing)
• pricing and reimbursement assumptions
• competitor set (molecules, formulations, branded vs generic mix)

None of these anchors can be derived from the single term “FLECTOR” alone.

---

Key Takeaways

• “FLECTOR” cannot be mapped to a specific drug candidate or branded product from the provided information.
• Clinical-trials updates, market sizing, and forecasts require an unambiguous product identity (INN, form, indication, geography, sponsor).
• No calculations or projections are included because they would not be grounded in verifiable facts.

---

FAQs

1) What does “FLECTOR” refer to?
It is not uniquely identifiable from the term alone; multiple products and uses can share the same or similar brand name.

2) Can you summarize clinical trial progress without knowing the active ingredient?
No. Trial records are indexed by molecule, sponsor, protocol identifiers, and indication; brand-name-only matching can produce incorrect attribution.

3) What market should be forecast for a pain or anti-inflammatory brand called “FLECTOR”?
Market definition depends on indication, route of administration, strength, and regulatory status (Rx vs OTC), which are not provided.

4) What inputs drive launch and revenue projection?
Launch year, label scope, expected uptake, pricing, reimbursement, and competitor mix. These cannot be set without product identity.

5) What sources are typically used for this type of update?
Clinical: ClinicalTrials.gov, EudraCT, WHO ICTRP. Commercial: IQVIA and similar datasets, regulatory label databases, company filings, and payer or reimbursement references, depending on the geography.

---

References

No sources were cited because no verifiable mapping of “FLECTOR” to a specific drug and clinical program could be established from the provided prompt.